Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.2024.16432 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.
Molecules
November 2024
Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany.
Amidst the ongoing global challenge of the SARS-CoV-2 pandemic, the quest for effective antiviral medications remains paramount. This comprehensive review delves into the dynamic landscape of FDA-approved medications repurposed for COVID-19, categorized as antiviral and non-antiviral agents. Our focus extends beyond conventional narratives, encompassing vaccination targets, repurposing efficacy, clinical studies, innovative treatment modalities, and future outlooks.
View Article and Find Full Text PDFThe Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits.
JAMA
October 2024
Lead Senior Staff Writer, Medical News & Perspectives, JAMA.
Drug-Drug Interactions Between COVID-19 Treatments and Psychotropic Medications: An Updated Study.
Cureus
December 2023
College of Medicine, Florida International University, Herbert Wertheim College of Medicine, Florida, USA.
The recent evolution of coronavirus disease 2019 (COVID-19) treatments has created challenges for healthcare providers in terms of new potential interactions between these COVID-19 treatments and psychotropic drugs in patients with psychiatric disorders. Current clinical practice guidelines on managing interactions between psychotropic medications and COVID-19 treatments do not account for the newer COVID-19 medications. There is a need for updated patient management recommendations that take into account drug interactions between psychotropic drugs and the latest pharmacological approaches to COVID-19 treatment.
View Article and Find Full Text PDFApplications of peptide-functionalized or unfunctionalized selenium nanoparticles for the passivation of SARS-CoV-2 variants and the respiratory syncytial virus (RSV).
Colloids Surf B Biointerfaces
January 2024
Program in Materials Science, UFPI, Teresina, Brazil; School of Engineering, Saveetha University, Chennai, India; School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, China.
The SARS-CoV-2 Omicron subvariants BA.4, BA. 5 and XBB are currently causing a COVID resurgence due to their increased spreading and infectivity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!